Navigation Links
Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors
Date:2/15/2013

MUMBAI, February 15, 2013 /PRNewswire/ --

Bharatbook.com is pleased to announce a new research report on Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors (http://www.bharatbook.com/healthcare-market-research-reports/drivers-of-m-a-in-2013-2016-pi3ks-and-btk-inhibitors.html)

New targets/drugs remain an evergreen medical need to address the unmet need of drug resistance in the treatment of cancer. Large global pharma are constantly on the hunt for drugs with label expansion potential = Longevity and Blockbuster Potential! About $10b+ has already been invested in licensing /acquisition of PI3K and other kinase inhibitors/companies since the last five years. Scientific data on the role of PI3K, BTK kinase in cancer and clinical Proof of Concept (PoC) data of the PI3K, BTKs inhibitors have reached a critical mass and companies with focus in this sector are poised to offer better treatment options for unmet need in hematologic malignancies. We expect more acquisitions of the innovator companies and or handsome licensing deals for unpartnered products as mature data and approvals come in the next few years. This report highlights the recent progress on the understanding of PI3Ks/BTK signaling pathway and companies developing PI3K/BTK inhibitors, the clinical data and competition.

     (Logo: http://photos.prnewswire.com/prnh/20130128/590935)

Key Points Discussed in the Report

  • Drugs in the pipeline

PI3K inhibitors - Infinity pharma (INFI), Gilead (GILD)

Dual PI3K inhibitor - Onconova/SymBio, Curis (CRIS)

BTK-inhibitors - Safety and clinical efficacy set it apart - Pharmacyclics (PCYC), Celgene (CELG)

  • M&A in Kinase Inhibitors in the last
    '/>"/>

SOURCE Bharat Book Bureau
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Womens Health Expert GC-Rise Ties up with Georgetown MBA Team to Tap M&A Potential and Growth Strategy
2. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
3. Kinase Inhibitors: Global Markets -- Focus on the U.S.
4. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
5. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
6. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... A recent study from researchers in ... find that those who took probiotics were able to run ... study showed that in extreme heat conditions, probiotics were able ... acne treatment explains what this new discovery means ... their skin condition. , While researchers tote the benefits ...
(Date:5/21/2013)... -- First patients dosed with PSX1002, an ... using Prosonix, particle engineering platform Prosonix, an ... Respiratory Medicines by Design , has initiated a ... its effect on lung function and the safety of ... severe chronic obstructive pulmonary disease (COPD). The first two ...
(Date:5/21/2013)... May 21, 2013 Custom Learning ... reporting eLearning solution using Tin Can API combined ... tool. CLD is a leading developer of training ... device companies worldwide. , Tin Can API ... helps learners and trainers more accurately measure the ...
(Date:5/21/2013)... Alpha Source, Inc., a Wisconsin-based ... exhibiting for the 13th consecutive year at the ... 2013 Conference and Expo. The conference brings together ... healthcare technologies. This year’s event will be held ... , The three-day event draws over 1,500 healthcare ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares Insight on New Findings Between Probiotics and Heat Tolerance, and What It Means for Acne Sufferers 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2
... It's been a long campaign season, and you've been poked ... national press corps member. John Kerry drank a beer at ... at your local kindergarten. Dick Cheney was spotted more in ... in the last four years. John Edwards has been in ...
... drug purification products Business filings serves ... dip in third-quarter earnings from mild weather ... Wisconsin-based Analogix joins French company to ... maker of drug-purification devices based in Burlington, Wisconsin, has ...
... more hours in the day so I can get more done (like ... We "fall back" into standard time and get another hour. But what ... my desk, which I always promise to do when I have more ... wanted to share in this column. Here they are, in no particular ...
Cached Biology Technology:Twenty ways you can tell this campaign has finally pushed you over the edge 2Tech Digest: whats moving in the Midwest (11/1/04) 2Music, mail, databases and printing from a technologists desk 2Music, mail, databases and printing from a technologists desk 3
(Date:5/21/2013)... The largest gathering of biomass experts , ... , When? 03-07 June 2013 ... scientific research, resource assessment, market and policy developments, manufacturing ... the world and benefiting from its 2013 edition from ... more than 60 countries, more than 240 plenary and ...
(Date:5/21/2013)... May 21, 2013 Royal Philips Electronics (NYSE: ... world,s first portable ultrasound with Philips, industry leading Live ... The CX50 xMATRIX with available Live 3D TEE and ... at the EuroPCR, official meeting for the European ... Since its launch in 2012, Philips CX50 xMATRIX ...
(Date:5/20/2013)... antibiotic colistin are also commonly resistant to antimicrobial ... a study in mBio , the online ... Cross-resistance to colistin and host antimicrobials LL-37 and ... attack, could mean that patients with life-threatening multi-drug ... immune response. Colistin is a last-line drug for ...
Breaking Biology News(10 mins):21st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... Alabama used worms to reel in information that they hope ... may be exploited to treat epilepsy. In a new research ... the researchers explain how the transparent roundworm, C. elegans ... transport of a molecule (gamma-aminobutyric acid or "GABA") that if ...
... b3c newswire / - Critical Outcome Technologies ... from animal experiments carried out at a prominent Canadian ... to the already impressive data package for COTI-2, demonstrating ... first line therapies with low toxicity in seven different ...
... the primary cause of cancer mortality in children. Even ... tremendously from the stressful treatment which can be harmful ... need for target-oriented, gentle treatment methods. The most important ... approximately one hundred young patients each year in Germany, ...
Cached Biology News:More than fish bait: Worms unlock secrets to new epilepsy treatments 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 3ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 4Germany starts its part in the International Cancer Genome Project 2Germany starts its part in the International Cancer Genome Project 3Germany starts its part in the International Cancer Genome Project 4
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Biology Products: